Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
HCW Biologics Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/24/2023 |
8-K
| Other Events Interactive Data |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q/A
| Quarterly Report for the period ended March 31, 2023 [amend] |
| 06/15/2023 |
4
| Winer Gary M (Director) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Granted 12,500 options to buy
@ $2.01, valued at
$25.1k
|
|
| 06/15/2023 |
4
| GARRETT SCOTT T (Director) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Granted 12,500 options to buy
@ $2.01, valued at
$25.1k
|
|
| 06/15/2023 |
4
| Greene Rick S. (Director) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Granted 12,500 options to buy
@ $2.01, valued at
$25.1k
|
|
| 06/15/2023 |
4
| Giles Lisa M. (Director) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Granted 12,500 options to buy
@ $2.01, valued at
$25.1k
|
|
| 06/09/2023 |
4
| Flowers Lee (SVP of Business Development) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 10,000 shares
@ $2.1574, valued at
$21.6k
Exercised 5,356 options to buy
@ $0.14, valued at
$749.8 |
|
| 06/09/2023 |
4
| Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 20,000 shares
@ $2.0643, valued at
$41.3k
|
|
| 06/08/2023 |
4
| Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 20,000 shares
@ $2.0316, valued at
$40.6k
Bought 4,696 shares
@ $2.212, valued at
$10.4k
|
|
| 06/07/2023 |
4
| Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 20,000 shares
@ $1.6672, valued at
$33.3k
Bought 19,062 shares
@ $1.8245, valued at
$34.8k
|
|
| 06/02/2023 |
4
| Wong Hing C (CEO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 800 shares
@ $1.6178, valued at
$1.3k
Bought 800 shares
@ $1.5353, valued at
$1.2k
|
|
| 06/01/2023 |
4
| Wong Hing C (CEO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 3,000 shares
@ $1.5527, valued at
$4.7k
Bought 2,000 shares
@ $1.546, valued at
$3.1k
|
|
| 06/01/2023 |
4
| Winer Gary M (Director) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 850 shares
@ $1.5206, valued at
$1.3k
Bought 500 shares
@ $1.5, valued at
$750 |
|
| 05/31/2023 |
4
| Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 20,000 shares
@ $1.6174, valued at
$32.3k
Bought 20,000 shares
@ $1.6598, valued at
$33.2k
|
|
| 05/24/2023 |
4
| Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 33,450 shares
@ $1.526, valued at
$51k
Bought 5,036 shares
@ $1.5662, valued at
$7.9k
Bought 20,000 shares
@ $1.6075, valued at
$32.2k
|
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
8-K
| Quarterly results |
| 03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/28/2023 |
8-K
| Quarterly results |
| 12/07/2022 |
8-K
| Other Events Interactive Data |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Quarterly results|
Docs:
|
"HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights Miramar, FL – November 7, 2022 – -- HCW Biologics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2022. Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, stated, “We are pleased to report that during the third quarter we opened three clinical sites for our second clinical trial to evaluate HCW9218 in patients with advanced pancreatic cancer. HonorHealth Research Institute was the first clinical site to dose a patie..." |
|
| 11/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/15/2022 |
4
| Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 15,000 shares
@ $2.5767, valued at
$38.7k
|
|
| 09/14/2022 |
4
| Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 15,000 shares
@ $2.6509, valued at
$39.8k
Bought 15,000 shares
@ $2.5767, valued at
$38.7k
|
|
| 09/12/2022 |
4
| Wong Hing C (CEO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 4,000 shares
@ $2.67, valued at
$10.7k
Bought 6,000 shares
@ $2.7, valued at
$16.2k
|
|
| 09/07/2022 |
4
| Wong Hing C (CEO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 4,000 shares
@ $2.55, valued at
$10.2k
Bought 6,000 shares
@ $2.58, valued at
$15.5k
|
|
| 09/01/2022 |
4
| Byam Rebecca (CFO) has filed a Form 4 on HCW Biologics Inc.|
Txns:
| Bought 7,200 shares
@ $2.5474, valued at
$18.3k
Bought 10,000 shares
@ $2.5572, valued at
$25.6k
|
|
|
|
|